Resveratrol Increases Serum BDNF Concentrations and Reduces Vascular Smooth Muscle Cells Contractility via a NOS-3-Independent Mechanism

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Wiciński, Michał ^a   Malinowski, Bartosz ^a   Wȩclewicz, Mateusz M ^a   Grześk, Elzbieta ^a   Grześk, Grzegorz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; RESVERATROL; N(G) NITROARGININE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; NOS3 PROTEIN, RAT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; LONG TERM CARE; MALE; NONHUMAN; PERFUSION PRESSURE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; SMOOTH MUSCLE CONTRACTILITY; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ARTERY; BLOOD; BRAIN CIRCULATION; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; MUSCLE CONTRACTION; PATHOPHYSIOLOGY; PERFUSION; RANDOMIZATION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTERIES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; PERFUSION; PHENYLEPHRINE; RANDOM ALLOCATION; RATS; RATS, WISTAR; STILBENES;

EID: 85013361053     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/9202954     Document Type: Article

References (43)

1. P. Saiko, A. Szakmary, W. Jaeger, and T. Szekeres, "Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerativemaladies or just a fad" Mutation Research-Reviews inMutation Research, vol. 658, no. 1-2, pp. 68-94, 2008.
2. M. A. Markus and B. J. Morris, "Resveratrol in prevention and treatment of common clinical conditions of aging, " Journal of Clinical Interventions in Aging, vol. 3, no. 2, pp. 321-329, 2008.
3. J. Li, L. Feng, Y. Xing et al., "Radioprotective and antioxidant effect of resveratrol in hippocampus by activating Sirt1, " International Journal of Molecular Sciences, vol. 15, no. 4, pp. 5928-5939, 2014.
4. H. Capiralla, V. Vingtdeux, H. Zhao et al., "Resveratrolmitigates lipopolysaccharide-and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-kB/STAT signaling cascade, " Journal of Neurochemistry, vol. 120, no. 3, pp. 461-472, 2012.
5. D. Albani, L. Polito, A. Signorini, and G. Forloni, "Neuroprotective properties of resveratrol in different neurodegenerative disorders, " BioFactors, vol. 36, no. 5, pp. 370-376, 2010.
6. E. Tellone, A. Galtieri, A. Russo, B. Giardina, and S. Ficarra, "Resveratrol: a focus on several neurodegenerative diseases, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 392169, 14 pages, 2015.
7. X. Ma, Z. Sun, Y. Liu, Y. Jia, B. Zhang, and J. Zhang, "Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia, " Neural Regeneration Research, vol. 8, no. 22, pp. 2050-2059, 2013.
8. Y. Béjot, A. Prigent-Tessier, C. Cachia et al., "Time-dependent contribution of non neuronal cells to BDNF production after ischemic stroke in rats, " Neurochemistry International, vol. 58, no. 1, pp. 102-111, 2011.
9. S. Cohen-Cory, A. H. Kidane, N. J. Shirkey, and S. Marshak, "Brain-derived neurotrophic factor and the development of structural neuronal connectivity, " Developmental Neurobiology, vol. 70, no. 5, pp. 271-288, 2010.
10. K. Miyake, W. Yamamoto, M. Tadokoro et al., "Alterations in hippocampal GAP-43, BDNF, and L1 following sustained cerebral ischemia, " Brain Research, vol. 935, no. 1-2, pp. 24-31, 2002.
11. D. K. Binder and H. E. Scharfman, "Brain-derived neurotrophic factor, " Growth Factors, vol. 22, no. 3, pp. 123-131, 2004.
12. G. Weinstein, A. S. Beiser, S. H. Choi et al., "Serum brainderived neurotrophic factor and the risk for dementia, " JAMA Neurology, vol. 71, no. 1, pp. 55-61, 2014.
13. F. Fumagalli, G. Racagni, and M. A. Riva, "Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease, " The Pharmacogenomics Journal, vol. 6, no. 2, pp. 95-104, 2006.
14. E. Tongiorgi, A. Sartori, G. Baj et al., "Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis, " Journal of the Neurological Sciences, vol. 320, no. 1-2, pp. 161-165, 2012.
15. M. Ventriglia, R. Zanardini, C. Bonomini et al., "Serum brainderived neurotrophic factor levels in different neurological diseases, " BioMed Research International, vol. 2013, Article ID 901082, 7 pages, 2013.
16. J. M. Conner, J. C. Lauterborn, Q. Yan, C. M. Gall, and S. Varon, "Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport, " Journal of Neuroscience, vol. 17, no. 7, pp. 2295-2313, 1997.
17. H. F. Farhadi, S. J. Mowla, K. Petrecca, S. J. Morris, N. G. Seidah, and R. A. Murphy, "Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brainderived neurotrophic factor, " Journal of Neuroscience, vol. 20, no. 11, pp. 4059-4068, 2000.
18. J. P. Fawcett, M. A. Alonso-Vanegas, S. J. Morris, F. D. Miller, A. F. Sadikot, and R. A. Murphy, "Evidence that brain-derived neurotrophic factor frompresynaptic nerve terminals regulates the phenotype of calbindin-containing neurons in the lateral septum, " Journal of Neuroscience, vol. 20, no. 1, pp. 274-282, 2000.
19. J. Goggi, I. A. Pullar, S. L. Carney, and H. F. Bradford, "The control of [125I]BDNF release from striatal rat brain slices, " Brain Research, vol. 967, no. 1-2, pp. 201-209, 2003.
20. P. Rasmussen, P. Brassard, H. Adser et al., "Evidence for a release of brain-derived neurotrophic factor from the brain during exercise, " Experimental Physiology, vol. 94, no. 10, pp. 1062-1069, 2009.
21. S. Guo, W. J. Kim, J. Lok et al., "Neuroprotection via matrixtrophic coupling between cerebral endothelial cells and neurons, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 21, pp. 7582-7587, 2008.
22. A. H. Nagahara and M. H. Tuszynski, "Potential therapeutic uses of BDNF in neurological and psychiatric disorders, " Nature Reviews Drug Discovery, vol. 10, no. 3, pp. 209-219, 2011.
23. S. M. Massa, T. Yang, Y. Xie et al., "Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents, "The Journal of Clinical Investigation, vol. 120, no. 5, pp. 1774-1785, 2010.
24. D. P. Ankeny, D. M. McTigue, Z. Guan et al., "Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury, " Experimental Neurology, vol. 170, no. 1, pp. 85-100, 2001.
25. P. B. Gorelick, A. Scuteri, S. E. Black et al., "Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/ American Stroke Association, " Stroke, vol. 42, no. 9, pp. 2672-2713, 2011.
26. R. Araya, T. Noguchi, M. Yuhki et al., "Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice, " Neurobiology of Disease, vol. 24, no. 2, pp. 334-344, 2006.
27. M. Rahvar, M. Nikseresht, S. M. Shafiee et al., "Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain, " Neurochemical Research, vol. 36, no. 5, pp. 761-765, 2011.
28. A. B. Klein, R. Williamson, M. A. Santini et al., "Blood BDNF concentrations reflect brain-tissue BDNF levels across species, " International Journal of Neuropsychopharmacology, vol. 14, no. 3, pp. 347-353, 2011.
29. G. Grzésk, M. Kozinski, U. S. Tantry et al., "High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells, " BioMed Research International, vol. 2013, Article ID 928271, 8 pages, 2013.
30. G. Grzésk, M. Wicínski, B. Malinowski et al., "Calciumblockers inhibit cyclosporine A-induced hyperreactivity of vascular smooth muscle cells, " Molecular Medicine Reports, vol. 5, no. 6, pp. 1469-1474, 2012.
31. S. Pfeiffer, E. Leopold, K. Schmidt, F. Brunner, and B. Mayer, "Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine, " British Journal of Pharmacology, vol. 118, no. 6, pp. 1433-1440, 1996.
32. E. Grzésk, B. Malinowski, M. Wicínski et al., "Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smoothmuscle cells, " Pharmacological Reports, vol. 68, no. 1, pp. 201-205, 2016.
33. S. Jeon, C.-H. Lee, Q. F. E. Liu, G. W. O. Kim, B.-S. Koo, and S. C. H. Pak, "Alteration in brain-derived neurotrophic factor (BDNF) after treatment of mice with herbal mixture containing Euphoria longana, Houttuynia cordata and Dioscorea japonica, " Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences, vol. 22, 2014.
34. Q. Wang, J. Xu, G. E. Rottinghaus et al., "Resveratrol protects against global cerebral ischemic injury in gerbils, " Brain Research, vol. 958, no. 2, pp. 439-447, 2002.
35. F. Zhang, Y.-F. Lu, Q. Wu, J. Liu, and J.-S. Shi, "Resveratrol promotes neurotrophic factor release from astroglia, " Experimental Biology and Medicine, vol. 237, no. 8, pp. 943-948, 2012.
36. L. W. Kline and E. Karpinski, "The resveratrol-induced relaxation of cholecystokinin octapeptide-or KCl-induced tension in male guinea pig gallbladder strips ismediated through L-type Ca2+ channels, " Journal of Neurogastroenterology and Motility, vol. 21, no. 1, pp. 62-68, 2015.
37. S. Park, F. Ahmad, A. Philp et al., "Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases, " Cell, vol. 148, no. 3, pp. 421-433, 2012.
38. Y. Zeng and K. Yang, "Sirtuin 1 participates in the process of age-related retinal degeneration, " Biochemical and Biophysical Research Communications, vol. 468, no. 1-2, pp. 167-172, 2015.
39. D. Liu, K. Xie, X. Yang et al., "Resveratrol reverses the effects of chronic unpredictable mild stress on behavior, serum corticosterone levels and BDNF expression in rats, " Behavioural Brain Research, vol. 264, pp. 9-16, 2014.
40. K. Taguchi, M. Ueda, and T. Kubo, "Effects of cAMP and cGMP on L-type calcium channel currents in rat mesenteric artery cells, " Japanese Journal of Pharmacology, vol. 74, no. 2, pp. 179-186, 1997.
41. N. Xia, U. Förstermann, and H. Li, "Resveratrol and endothelial Nitric oxide, " Molecules, vol. 19, no. 10, pp. 16102-16121, 2014.
42. V. Leblais, S. Krisa, J. Valls et al., "Relaxation induced by red wine polyphenolic compounds in rat pulmonary arteries: lack of inhibition by NO-synthase inhibitor, " Fundamental & Clinical Pharmacology, vol. 22, no. 1, pp. 25-35, 2008.
43. P. W. Pires, C. M. Dams Ramos, N. Matin, and A. M. Dorrance, "The effects of hypertension on the cerebral circulation, " AJP: Heart and Circulatory Physiology, vol. 304, no. 12, pp. H1598-H1614, 2013.